Tazemetostat, the first in a new class of drugs, shows promising efficacy and a favourable safety profile in people with relapsed or refractory follicular lymphoma.
Updated guidelines give recommendations for treatment of people with Waldenström’s macroglobulinaemia.
New European guidelines give evidence-based recommendations for the diagnosis, treatment and follow-up of people with CLL.
Lenalidomide plus rituximab is now available on the NHS in Scotland for relapsed or refractory follicular lymphoma, while ibrutinib has been approved for NHS use in people with relapsed or refractory Waldenström’s macroglobulinaemia.
Lymphoma Action ensure that the patient voice is heard at HTAs, resulting in better access to the latest treatments.
The National Institutes for Health and Care Excellence (NICE) has approved polatuzumab vedotin for use on the NHS in people with diffuse large B-cell lymphoma (DLBCL).
Have your say on chlormethine gel for mycosis fungoides - consultation runs until 26 August.
The European Medicines Agency has approved acalabrutinib for chronic lymphocytic leukaemia (CLL).
Updated guidelines for the diagnosis and treatment of people with follicular lymphoma.
Brentuximab vedotin is to be available on the NHS for first-line treatment of anaplastic large cell lymphoma.
Acalabrutinib shows potential as a chemotherapy-free treatment option for people with CLL who have not been treated before.
The European Medicines Agency has approved brentuximab vedotin for first-line treatment of anaplastic large cell lymphoma.
Obinutuzumab plus bendamustine routinely available on the NHS for people with follicular lymphoma who have not responded to rituximab.
New European guidelines give evidence-based recommendations for the diagnosis, treatment and follow-up of people with marginal zone lymphoma.
NICE approves new, chemotherapy-free treatment option - lenalidomide in combination with rituximab.
The European Medicines Agency has extended the licensed indications for two lymphoma treatments: rituximab and venetoclax.
Brentuximab vedotin (Adcetris®) is now available on the NHS in Scotland for adults with some advanced T-cell skin lymphomas.
US company gets the go-ahead to start a trial of 'off-the-shelf' CAR T-cell therapy for people with lymphoma.
The European Medicines Agency has recommended new treatment options for people with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
Axicabtagene ciloleucel (Yescarta®) is now available on the NHS in Scotland.
NICE not recommending idelalisib for use on the NHS for people with refractory follicular lymphoma.
Good news that tisagenlecleucel (Kymriah®) is now available on the NHS in Scotland
Lymphoma Action is continually pushing for improvements in the access to, and delivery of, CAR T-cell therapy to allow everybody who is suitable for treatment to access it.
It is true that CAR T-cells are a new type of treatment that could transform the prognosis for some people with difficult-to-treat lymphoma. However, it can have serious side effects and research is still ongoing to find out the long-term effects of the treatment.
NICE approves brentuximab vedotin for advanced primary cutaneous anaplastic large cell lymphoma, mycosis fungoides and Sézary syndrome.
The British Society of Haematology has released new guidelines on the diagnosis and treatment of PMBCL.
Tisagenlecleucel (Kymriah®) not available for use on the NHS in Scotland
British Association of Dermatologists publishes new guidelines for the management of primary cutaneous lymphomas
The Scottish Medicines Consortium is not recommending axicabtagene ciloleucel (Yescarta®) for use within NHS Scotland
New CAR T-cell therapies will be available for selected people with relapsed or refractory large B‑cell lymphoma
Venetoclax plus rituximab is now available on the NHS for adults with relapsed or refractory CLL
Mogamulizumab licensed for the treatment of mycosis fungoides or Sézary syndrome (SS)
Have your say on brentuximab vedotin for cutaneous T-cell lymphoma
Have your say on bendamustine with rituximab for relapsed low-grade non-Hodgkin lymphoma.
New guidelines give a clear treatment pathway for people with primary CNS lymphoma
Stephen Scowcroft, our Business Development Manager, reports back from the European Society of Medical Oncology (ESMO) Congress 2018 #ESMO18.
NICE recommending Kymriah for young people with B-cell acute lymphoblastic leukaemia (ALL)
Medicinal cannabis can now be prescribed for adults with chemotherapy-related nausea or vomiting, who haven't responded to licensed treatment.
Ground-breaking treatment offers new hope.
Education and Training Manager Helen Mee reflects on the first of a series of conferences for people with lymphoma
Newer antibody still not recommended in Scotland
Your insight could support a NICE assessment for brentuximab vedotin
Our response to the NICE draft decision to reject CAR T-cell technology on the NHS.
Dr Becky Salisbury, our Senior Medical Writer, blogs about one of the hot topics from the recent British Society of Haematology meeting.
Positive update about ibrutinib and relapsed chronic lymphocytic leukaemia (CLL)
This report from the annual meeting of the British Society of Haematology discusses reducing treatment for Hodgkin lymphoma to reduce side effects.
NICE/NHS England recommend pembrolizumab for people with relapsed or refractory Hodgkin lymphoma who have had brentuximab vedotin and cannot have an autologous stem cell transplant
The British Society of Haematology have published their guidelines on the treatment of chronic lymphocytic leukaemia
New guidelines give a clear treatment pathway for people with mantle cell lymphoma
These therapies offer a new treatment option for people with difficult-to-treat B cell lymphomas.
Stephen Scowcroft reports back from a biosimilars panel at the European Haematology Association (EHA) Congress 2018.
New evidence means the targeted drug can now be used routinely on the NHS for more people with classical Hodgkin lymphoma.
NICE recommends obinutuzimab (Gazyvaro) to be considered as part of first-line treatment for advanced follicular lymphoma.
Scottish Medicines Consortium chooses not to recommend obinutuzumab for treatment of follicular lymphoma.
NICE reverses its decision on ibrutinib for relapsed or refractory mantle cell lymphoma.
NICE reverses decision on Ibrutinib and recommends it for baseline commissioning in England.
Brentuximab vedotin recommended as treatment option for systemic anaplastic large cell lymphoma.
Some people with CLL now able to access venetoclax through Cancer Drugs Fund.